The clinical value of p21(WAF1/CIP1) expression in superficial bladder cancer

Nan-Haw Chow, Tzong Shin Tzai, Hong-Lin Cheng, Hsiao-Sheng Liu, Shih-Huang Chan, Yat-Ching Tong

研究成果: Article同行評審

12 引文 斯高帕斯(Scopus)


The clinical value of p21(WAF1/CIP1) in superficial bladder cancer remains controversial. To address the question, we examined the expression patterns of p21 and p53 gene products and compared for their significance in a total of 89 cases of superficial (pTa/pT1) bladder cancer. Over-expression of p21 was detected in 32 of 89 (36%) tumors. But, the expression status did not correlate with biological indicators or clinical outcome (p > 0.1, respectively). Factors predicting clinical outcome were multiplicity for tumor recurrence (p = 0.0002) or patient survival (p = 0.03), and the histological grading for disease progression (p = 0.02) or patient survival (p = 0.05). Taking into account the p53 status, a trend approaching better prognosis for p53+p21+ tumors was observed compared with that of p53+p21- bladder cancer (p = 0.08). Our data indicate that evaluation of p21 status does not provide better prognostic information compared with conventional biological indicators of superficial bladder cancer. Maintenance of p21 appears to abrogate the deleterious effects of p53 alterations in the tumorigenesis of human bladder.

頁(從 - 到)1173-1176
期刊Anticancer Research
發行號2 B
出版狀態Published - 2000 1月 1

All Science Journal Classification (ASJC) codes

  • 腫瘤科
  • 癌症研究


深入研究「The clinical value of p21(WAF1/CIP1) expression in superficial bladder cancer」主題。共同形成了獨特的指紋。